PHR vs. MPLN, IRWD, GYRE, PRTA, CGEM, BLTE, WRBY, LGND, AHCO, and GMTX
Should you be buying Phreesia stock or one of its competitors? The main competitors of Phreesia include MultiPlan (MPLN), Ironwood Pharmaceuticals (IRWD), Gyre Therapeutics (GYRE), Prothena (PRTA), Cullinan Oncology (CGEM), Belite Bio (BLTE), Warby Parker (WRBY), Ligand Pharmaceuticals (LGND), AdaptHealth (AHCO), and Gemini Therapeutics (GMTX). These companies are all part of the "medical" sector.
MultiPlan (NYSE:MPLN) and Phreesia (NYSE:PHR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
In the previous week, MultiPlan had 4 more articles in the media than Phreesia. MarketBeat recorded 6 mentions for MultiPlan and 2 mentions for Phreesia. MultiPlan's average media sentiment score of 0.38 beat Phreesia's score of -0.11 indicating that Phreesia is being referred to more favorably in the news media.
MultiPlan presently has a consensus price target of $2.00, indicating a potential upside of 229.38%. Phreesia has a consensus price target of $31.62, indicating a potential upside of 43.97%. Given Phreesia's higher possible upside, research analysts plainly believe MultiPlan is more favorable than Phreesia.
Phreesia received 113 more outperform votes than MultiPlan when rated by MarketBeat users. Likewise, 64.74% of users gave Phreesia an outperform vote while only 41.67% of users gave MultiPlan an outperform vote.
MultiPlan has higher revenue and earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than MultiPlan, indicating that it is currently the more affordable of the two stocks.
MultiPlan has a net margin of -9.54% compared to MultiPlan's net margin of -38.42%. Phreesia's return on equity of -8.31% beat MultiPlan's return on equity.
MultiPlan has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Phreesia has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.
87.2% of MultiPlan shares are held by institutional investors. Comparatively, 92.1% of Phreesia shares are held by institutional investors. 8.2% of MultiPlan shares are held by company insiders. Comparatively, 5.8% of Phreesia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
MultiPlan beats Phreesia on 10 of the 17 factors compared between the two stocks.
Get Phreesia News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phreesia Competitors List
Related Companies and Tools
